These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16243811)

  • 1. 14-3-3sigma in endometrial cancer--a possible prognostic marker in early-stage cancer.
    Ito K; Suzuki T; Akahira J; Sakuma M; Saitou S; Okamoto S; Niikura H; Okamura K; Yaegashi N; Sasano H; Inoue S
    Clin Cancer Res; 2005 Oct; 11(20):7384-91. PubMed ID: 16243811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of p53 overexpression in endometrial cancer.
    Ito K; Watanabe K; Nasim S; Sasano H; Sato S; Yajima A; Silverberg SG; Garrett CT
    Cancer Res; 1994 Sep; 54(17):4667-70. PubMed ID: 8062261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
    Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
    Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
    Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
    Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas.
    Salvesen HB; Iversen OE; Akslen LA
    Clin Cancer Res; 1998 Nov; 4(11):2779-85. PubMed ID: 9829742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of E-cadherin protein expression in pathological stage I-III endometrial cancer.
    Mell LK; Meyer JJ; Tretiakova M; Khramtsov A; Gong C; Yamada SD; Montag AG; Mundt AJ
    Clin Cancer Res; 2004 Aug; 10(16):5546-53. PubMed ID: 15328195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological significance of fragile histidine triad transcription protein expression in endometrial carcinomas.
    Segawa T; Sasagawa T; Saijoh K; Inoue M
    Clin Cancer Res; 2000 Jun; 6(6):2341-8. PubMed ID: 10873085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
    Powell MA; Mutch DG; Rader JS; Herzog TJ; Huang TH; Goodfellow PJ
    Cancer; 2002 Jun; 94(11):2941-52. PubMed ID: 12115383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
    Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
    Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
    Salvesen HB; Das S; Akslen LA
    Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
    Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
    Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.
    Oreskovic S; Babic D; Kalafatic D; Barisic D; Beketic-Oreskovic L
    Gynecol Oncol; 2004 Apr; 93(1):34-40. PubMed ID: 15047211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer.
    Ferrandina G; Ranelletti FO; Gallotta V; Martinelli E; Zannoni GF; Gessi M; Scambia G
    Gynecol Oncol; 2005 Sep; 98(3):383-9. PubMed ID: 15979129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.
    Kounelis S; Kapranos N; Kouri E; Coppola D; Papadaki H; Jones MW
    Mod Pathol; 2000 Apr; 13(4):379-88. PubMed ID: 10786803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
    Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
    Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
    Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
    Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
    Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
    Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.